Literature DB >> 32549771

Can neutrophil/lymphocyte ratio be used as an indicator of inflammation in patients with hyperthyroidism?

Murat Dağdeviren1, Tolga Akkan1, Dilek Yapar2, Serdar Karakaya2, Tanyel Dağdeviren3, Derun Ertuğrul1, Mustafa Altay1.   

Abstract

BACKGROUND: In our study, we aimed to evaluate changes in the neutrophil and lymphocyte series and investigate whether the neutrophil/lymphocyte ratio (NLR) is indicative of inflammations in patients with hyperthyroidism.
METHODS: A total of 161 patients were enrolled, 121 of which had hyperthyroidism (71 Graves' Disease (GD) and 50 non-Graves hyperthyroidism (NGH) patients) and 40 of which were control group members. Retrospectively, patients' neutrophil and lymphocyte counts were taken, and the NLR was calculated.
RESULTS: While the number of neutrophils was significantly lower in the GD group (p = 0.003), there was no significant difference between the NGH and the control group. In the GD group, NLR values were significantly lower than the other two groups (median 1.39 for GD, median 1.84 for NGH and median 1.83 for the control group, p < 0.001). Only three patients in the GD group had neutropenia. There was also a significant negative correlation between free T3 and neutrophil count and NLR in hyperthyroid patients (r = -0.28, p = 0.001 and r = -0.34, p < 0.001, respectively).
CONCLUSIONS: In our study, we found that NLR did not in crease in hyperthyroid patients and that this ratio decreased due to the decrease in neutrophil levels in GD. We thus concluded that NLR is not a suitable indicator of hyperthyroidism. Murat Dağdeviren, Tolga Akkan, Dilek Yapar, Serdar Karakaya, Tanyel Dağdeviren, Derun Ertuğrul, Mustafa Altay, published by CEON/CEES.

Entities:  

Keywords:  hyperthyroidism; lymphocyte; neutrophil; ratio

Year:  2020        PMID: 32549771      PMCID: PMC7282227          DOI: 10.2478/jomb-2019-0004

Source DB:  PubMed          Journal:  J Med Biochem        ISSN: 1452-8266            Impact factor:   3.402


  26 in total

Review 1.  Propylthiouracil-induced agranulocytosis: an unusual presentation and a possible mechanism.

Authors:  E L Toth; M J Mant; S Shivji; J Ginsberg
Journal:  Am J Med       Date:  1988-11       Impact factor: 4.965

2.  Characterization of the natural killer cell activity in Hashimoto's and Graves' diseases.

Authors:  B K Pedersen; U Feldt-Rasmussen; K Bech; H Perrild; K Klarlund; M Høier-Madsen
Journal:  Allergy       Date:  1989-09       Impact factor: 13.146

3.  Peripheral blood leucocytes in thyrotoxicosis (Graves' disease) as studied by conventional light microscopy.

Authors:  W J Irvine; F C Wu; S J Urbaniak; F Toolis
Journal:  Clin Exp Immunol       Date:  1977-02       Impact factor: 4.330

4.  Pancytopenia responding to treatment of hyperthyroidism: a clinical case and review of the literature.

Authors:  B Shaw; A B Mehta
Journal:  Clin Lab Haematol       Date:  2002-12

5.  The relationship between hyperthyroidism and the distribution of peripheral blood T, NK and B-lymphocytes in multinodular goiter.

Authors:  J J Corrales; A Orfao; J M Miralles; J San Miguel
Journal:  Horm Metab Res       Date:  1994-02       Impact factor: 2.936

6.  Relation of neutrophil to lymphocyte ratio with the presence and severity of stable coronary artery disease.

Authors:  Ahmet Kaya; Mustafa Kurt; Ibrahim Halil Tanboga; Turgay Işık; Zeki Yüksel Günaydın; Yasemin Kaya; Selim Topçu; Serdar Sevimli
Journal:  Clin Appl Thromb Hemost       Date:  2013-01-23       Impact factor: 2.389

7.  Treatment of hyperthyroidism with antithyroid drugs corrects mild neutropenia in Graves' disease.

Authors:  N Aggarwal; S A Tee; W Saqib; T Fretwell; G P Summerfield; S Razvi
Journal:  Clin Endocrinol (Oxf)       Date:  2016-07-21       Impact factor: 3.478

8.  The influence of 3,3',5-triiodo-L-thyronine on human haematopoiesis.

Authors:  K Grymuła; E Paczkowska; V Dziedziejko; M Baśkiewicz-Masiuk; M Kawa; B Baumert; Z Celewicz; E Gawrych; B Machaliński
Journal:  Cell Prolif       Date:  2007-06       Impact factor: 6.831

9.  High Frequency of Thyroid Disorders in Patients Presenting With Neutropenia to an Outpatient Hematology Clinic STROBE-Compliant Article.

Authors:  Eleni Magdalini A Kyritsi; Xanthi Yiakoumis; Gerasimos A Pangalis; Charalampos Pontikoglou; Katerina Pyrovolaki; Christina Kalpadakis; Irini Mavroudi; Helen Koutala; Semeli Mastrodemou; Theodoros P Vassilakopoulos; George Vaiopoulos; Evanthia Diamanti-Kandarakis; Helen A Papadaki; Maria K Angelopoulou
Journal:  Medicine (Baltimore)       Date:  2015-06       Impact factor: 1.889

10.  Alteration in Prooxidant-antioxidant Balance Associated with Selenium Concentration in Patients with Congenital Hypothyroidism.

Authors:  Shilan Rostami; Asadollah Fathollahpour; Mohammad Abdi; Kejal Naderi
Journal:  J Med Biochem       Date:  2018-07-01       Impact factor: 3.402

View more
  4 in total

1.  Treatment of Graves' Disease Associated With Severe Neutropenia.

Authors:  Soukaina Laidi; Imane Motaib; Saloua Elamari; Said Anajar; Asma Chadli
Journal:  Cureus       Date:  2022-01-07

2.  Increased maternal leptin levels may be an indicator of subclinical hypothyroidism in a newborn.

Authors:  Hande Karpuzoglu; Yasemin Ucal; Pinar Kumru; Murat Muhcu; Mustafa Eroglu; Muhittin Serdar; Mustafa Serteser; Aysel Ozpinar
Journal:  J Med Biochem       Date:  2022-04-08       Impact factor: 2.157

3.  Specific impact of cardiovascular risk factors on coronary microcirculation in patients with subclinical hypothyroidism.

Authors:  Mirjana Stojković; Biljana Nedeljković-Beleslin; Milorad Tešić; Zoran Bukumirić; Jasmina Ćirić; Miloš Stojanović; Marija Miletić; Ana Đorđević-Dikić; Vojislav Giga; Branko Beleslin; Miloš Žarković
Journal:  J Med Biochem       Date:  2022-07-29       Impact factor: 2.157

4.  Neutrophil-to-lymphocyte Ratio is Associated with LV Diastolic Dysfunction in the Overt Hyperthyroid Patients.

Authors:  Huan Zhang; Jiaoyue Zhang; Huan Li; Yaqiong Bi; Linfang Wang; Yuming Li
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-14       Impact factor: 6.055

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.